dr. stinchcombe discusses differences in toxicity profiles among alk inhibitors in nsclc
Published 5 years ago • 74 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
0:56
dr. stinchcombe on the alta-1l trial in alk nsclc
-
1:05
dr. stinchcombe on molecular testing in alk nsclc
-
1:32
dr. stinchcombe on remaining challenges in alk nsclc
-
6:41
next-generation alk inhibitors for nsclc
-
6:04
case study: progression on alk inhibitors in nsclc
-
6:27
alk inhibitor sequencing in nsclc
-
0:51
dr. stinchcombe discusses the pacific trial for nsclc
-
8:37
alk inhibition in nsclc
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
1:10
dr. stinchcombe on advances in targeted therapies in nsclc
-
5:18
utilizing next-generation alk inhibitors in nsclc
-
7:55
emerging checkpoint inhibitors for lung cancer
-
4:37
development of alk inhibitors in advanced non-small cell lung cancer
-
8:17
third-generation alk inhibitors for nsclc
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
3:59
alectinib in alk-mutated nsclc
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc